Imatinib TDM in GIST (NCT05493215)
A Phase 2 Study of Imatinib Therapeutic Drug Monitoring in Gastrointestinal Stromal Tumor
🩺 Plain-English Summary (8th-Grade Level)
Imatinib can lead to long recurrence free survival in patients diagnosed with gastrointestinal stromal tumors (GIST); however side effects can significantly hinder quality of life for our patients. This study will use therapeutic drug monitoring to improve quality of life and symptoms and assess how many patients maintain therapeutic levels. Free drug levels and pharmokinetics of imatinib will also be monitored.
Who can join: Review the eligibility criteria below.
Location: Markey Cancer Center — Lexington, Kentucky
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Markey Cancer Center — Lexington, Kentucky
📞 Contact the Study Coordinator
Phone: (859) 323-2354
Email: Yvonne.Taul@uky.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Gastrointestinal Stromal Tumors
- SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST — Miami, Florida
- A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib — Scottsdale, Arizona
- Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting. — Houston, Texas
- ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST — Miami, Florida
- Preoperative Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor — La Jolla, California
Explore by condition: All Gastrointestinal Stromal Tumors clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.